[go: up one dir, main page]

WO2010146536A1 - Suspension de particules comprenant un médicament - Google Patents

Suspension de particules comprenant un médicament Download PDF

Info

Publication number
WO2010146536A1
WO2010146536A1 PCT/IB2010/052676 IB2010052676W WO2010146536A1 WO 2010146536 A1 WO2010146536 A1 WO 2010146536A1 IB 2010052676 W IB2010052676 W IB 2010052676W WO 2010146536 A1 WO2010146536 A1 WO 2010146536A1
Authority
WO
WIPO (PCT)
Prior art keywords
suspension
particles
drug
matrix
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/052676
Other languages
English (en)
Inventor
Michel Paul Barbara Van Bruggen
David William Moss
Elena Dee Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVA BIO-PHARMA TECHNOLOGIES Ltd
Koninklijke Philips NV
Original Assignee
NOVA BIO-PHARMA TECHNOLOGIES Ltd
Koninklijke Philips Electronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVA BIO-PHARMA TECHNOLOGIES Ltd, Koninklijke Philips Electronics NV filed Critical NOVA BIO-PHARMA TECHNOLOGIES Ltd
Publication of WO2010146536A1 publication Critical patent/WO2010146536A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • the invention relates to a suspension for therapeutic use, to a method for preparing such suspension and to the use of such suspension for the treatment and/or prevention of a disease.
  • the invention further relates to a drug delivery device for delivering such suspension and to the use of such drug delivery device for the treatment and/or prevention of a disease.
  • GI gastrointestinal
  • biopharmaceuticals which effectiveness and toxicity would be significantly improved if they were administrated in a semi-continuous fashion, something that is practically not achievable with injections.
  • a controlled delivery of the bioactive agent from an implantable device over prolonged periods of time would have various potential advantages.
  • implanted delivery devices applied in clinical practice, mainly in palliative care and oncology.
  • the drugs that are administered comprise morphine, baclophen and floxuridine. See for example Fig. 1.
  • any drug has, however, a limited shelf-live, which decreases considerably with increasing temperature. Therefore any drug to be applied in any kind of drug delivery device needs to be protected against deterioration. This especially applies to the controlled delivery of proteins, proteinaceous compounds and nucleic acids which biological molecules have in common that they have a high molecular weight with often a complex structure and that they are typically marginally stable in aqueous formulations, exhibiting at room temperature a shelf live stability ranging from minutes to at maximum a few days. In this respect it is observed that only inherently tough small molecule drugs can survive in aqueous solution for a useful shelf life. The stabilization of biological complex molecules at ambient and physiological temperatures constitutes therefore a major challenge.
  • a problem associated to the use of suspensions that contain such micro particles in implantable pumps is the settling of the particles inside the device, which will strongly affect the safe and reliable functioning of the pump and thus the amount dosed per unit time. This means that within the timeframe the suspension is present inside the pump, the particles should not sediment.
  • Known methods that are aimed to deal with this sedimentation problem include the decrease of the density difference that exists between the particles and the dispersion medium used in the suspension, and the increase of the viscosity of the dispersion medium. The decrease of the density difference has, for instance, been described in WO 2005/099669.
  • a disadvantage of this approach is, however, that it relies on the use of perfluorocarbons and fluorinated ethers which may have the tendency not to result in stable dispersions, which is a strict requirement for accurately pumping suspensions out of a drug delivery device having a narrow orifice.
  • the increase of the viscosity of the dispersion medium has, for example, been described in EP 1755650 Bl. Ranges of 1 to 1000 kPoise (10 5 to 10 8 x the water viscosity) and more preferable ranges of 5-30 kPoise (5.10 5 to 3.10 6 x the water viscosity) are being mentioned.
  • a suspension for therapeutic use comprising - particles, and a liquid non-aqueous biocompatible or biodegradable vehicle wherein the particles do not dissolve, aggregate or sediment wherein the particles comprise a biocompatible or biodegradable matrix excipient forming an amorphous and chemically inert matrix, a drug preserved in the matrix, wherein the particles have an average particle diameter in suspension of between 0.1 and 100 ⁇ m, wherein the term 'average' refers the number average like being determined by e.g.
  • the matrix excipient is biocompatible or biodegradable and capable of forming a highly water soluble, amorphous and chemically inert (also over a period of one year) matrix.
  • Said matrix is capable of immobilizing and stabilizing the drug molecules at high temperatures (within relevant temperature range of say 36-41 degrees Celcius) for one year.
  • Said dispersion medium is preferably capable of preventing water or oxygen to reach and chemically react with said particles.
  • a glass matrix is suitable for suitably be made of a wide variety of glass forming compounds, optionally in the presence of a glass formation facilitator compound.
  • the matrix can suitably be made of sugar glass, metal carboxylate glass or phosphate glass.
  • the matrix is made of sugar glass.
  • matrix excipients forming a sugar glass include mannitol, inositol, trehalose, albumin and others. It is well known that such matrix excipients are an effective medium for the preservation of certain biological, proteinaceous, botanical and other organic materials. There is a considerable literature devoted to the theory of how sugar glasses exert this effect (e.g. Elbein, E. D et al., Glycobiology, 2003, 13, 17) and in particular in relation to vaccines (e.g. Maa, Y. F. et al., J Pharm Sci.
  • the particles preferably contain a high loading of the drug, preferably between 1 and 75 wt%, more preferably betweenl5 and 70 wt%, and in particular between 35 and 65 wt%.
  • the drug is preferably a protein, peptide, proteinaceous compound, vaccine or nucleic acid.
  • proteins and proteinaceous compounds can be applied in the present invention. Suitable examples of proteins and proteinaceous compounds include those proteins which have biological activity or which may be used to treat a disease or other pathological condition.
  • Factor VIII, Factor IX and other coagulation factors include, for instance, Factor VIII, Factor IX and other coagulation factors, chymotrypsin, trypsinogen, alpha-interferon, beta-interferon and other interferons, beta- galactosidase, lactate dehydrogenase, growth factors, clotting factors, enzymes, immune response stimulators, cytokines, lymphokines, immunoglobulins, interleukins, peptides, somatostatin, somatotropin analogues, somatomedin-C, Gonadotropic releasing hormone, follicle stimulating hormone, luteinizing hormone, LHRH, LHRH analogues such as leuprolide, nafarelin and goserelin, LHRH agonists and antagonists, growth hormone releasing factor, calcitonin, colchicine, gonadotropins such as chorionic gonadotropin, oxytocin, oc
  • agents that may be delivered include a, antitrypsin, insulin and other peptide hormones, adrenal cortical stimulating hormone, thyroid stimulating hormone, and other pituitary hormones erythropoietin, growth factors such as GCSF, GMCSF, insulin- like growth factor 1, tissue plasminogen activator, CF4, dDAVP, tumor necrosis factor receptor, pancreatic enzymes, lactase, interleukin-1 receptor antagonist, inter leukin-2, tumor suppresser proteins, cytotoxic proteins, retroviruses and other viruses, viral proteins, antibodies, recombinant antibodies, and antibody fragments.
  • growth factors such as GCSF, GMCSF, insulin- like growth factor 1, tissue plasminogen activator, CF4, dDAVP, tumor necrosis factor receptor, pancreatic enzymes, lactase, interleukin-1 receptor antagonist, inter leukin-2, tumor suppresser proteins, cytotoxic proteins, retroviruses and other viruses, viral proteins, antibodies, recombinant antibodies,
  • the drug is preferably selected from the group consisting of Factor IX, Factor VIII, interferon alpha, interferon beta, interferon omega, interferon gamma, beta- galactosidase, lactate dehydrogenase, chymotrypsin, trypsinogen, and (monoclonal) anibody, interleukin, insulin, coagulation factor, growth hormone, epoetin, anti-TNF-alpha, DNA, RNA, oligonucleotides, or any analogs thereof.
  • Interferons are a particularly preferred group of proteins to be used in the present invention.
  • Interferons are glycoprotein cytokines which are produced by cells in response to various stimuli such as exposure to virus, bacterium, parasite or other antigen.
  • Interferons display antiviral, immunomodulatory and antiproliferative activities, and they are used for treatments of viral hepatitis, multiple sclerosis and certain cancers. There is therefore a special interest to deliver interferons in a controlled manner over a prolonged period of time without intervention.
  • the present invention provides a system which facilitates this.
  • nucleic acid means unbranched (linear or circular) chains of nucleotides in which the 5' phosphoric group of each nucleotide is esterif ⁇ ed with the 3' hydroxyl of the adjoining nucleotide.
  • the term includes ribonucleic acid (RNA), deoxyribonucleic acid (DNA) constructs, and single and double stranded molecules, oligonucleotides, gene expression constructs, mRNA molecules, ribozymes, and the like.
  • the nucleic acid is suitably selected from the group consisting of DNA, RNA and oligonucleotides.
  • Naturally-derived or purified, synthetically produced and recombinantly produced moieties are all included in said term.
  • the term also includes analogs, derivatives, and constructs that include promoter, leader, signal, polyadenylation or intron sequences, locus control regions, markers, and the like.
  • Nucleic acids containing modified, derivatized or non-naturally occurring nucleotide units as part of their structure are also included in the term.
  • the nucleic acid is in the form of at least one selected from the group consisting of a nucleic acid/lipid complex, a nucleic acid-containing liposome, a ribozyme, a viral vector, a virosome, nucleic acid-containing dendrimers, nucleic acid-containing cationic polymers and nucleic acid-containing poly (lactic-co-glycolic)acid (PLGA) particles.
  • a nucleic acid/lipid complex means a complex that forms between nucleic acids and small, cationic unilamellar vesicles held together by electrostatic interactions rather than by encapsulation of the nucleic acids in liposomes.
  • liposome means the multi- or unilamellar vesicles formed from phospholipids which are used as carriers for drugs and macromolecules, especially nucleic acids.
  • the drug to be used in accordance with the present invention can be used in the form of a salt, preferably a pharmaceutically acceptable salt.
  • Useful salts are known to those of skill in the art and include salts with inorganic acids, organic acids, inorganic bases or organic bases.
  • the particle size distribution is a very relevant parameter that was optimized based on the intended use of the suspension. It was found that the smaller the average particle the more preferable because of the following observations:
  • the suspension according to the present invention has a size distribution of the particles such that at least 70 %, preferably 90 % and more preferably at least 99 % of the particles has a diameter smaller than 10 times the average diameter.
  • the suspension has a size distribution of the particles such that at least 70 %, preferably 90 % and more preferably at least 99 % of the particles has a diameter smaller than 5 times the average diameter. More preferably, the suspension has a size distribution of the particles such that at least 70 %, preferably 90 % and more preferably at least 99 % of the particles has a particle diameter smaller than 2 times the average diameter.
  • Fig. 4 shows a microscopic image of a solution according to the invention.
  • Fig. 5 shows an image from an electron microscope of particles according to the invention. The particles have been in a suspension of the invention. They have been taken out of the suspension by attaching them to a grid prior to making the image.
  • the particles do not dissolve in the vehicle, aggregate or sediment within the time frame of storage in the reservoir of the implantable pump. On the other hand, the particles need to dissolve quickly, preferably within minutes when brought into contact with water, without leaving residual material that cannot be removed easily from the body.
  • the particles to be used in the present invention can, for instance, be made by means of a spray drying process or other processes which have been described in WO 02/32402, which entire document is hereby incorporated by reference.
  • the vehicle has a viscosity of between 1 and 25 mPa.s, preferably between 3 and 15 mPa.s, more preferably between 5 and 10 mPa.s.
  • the vehicle has a vapor pressure of between 0.005 and 0.06 bar, preferably between 0.02and 0.05 bar, more preferably between 0.005 and 0.01 bar vapor pressure water at 37C is 0.06 bar
  • the vehicle has a boiling temperature of between 90 and 300 0 C, preferably between 130 and 300 0 C, more preferably between 180 and 250 0 C.
  • the vehicle has a density which is preferably between 0.5 and 1.5 g/mol, more preferably between 0.5 and 1.2 g/mol, in particular between 0.5 and 1.0 mol/g.
  • the solubility of water in the vehicle at 37 0 C is preferably between 0 and 0.1 mass% , more preferably between 0 and 0.7 mass%, in particular between 0 and 0.5 mass%.
  • a preferred vehicle is non-aqueous, anhydrous, aprotic, non-polar, hydrophobic and has low reactivity.
  • Colloidal stability of the suspension is of high importance and can be realized by selecting a vehicle having the unique property of stabilizing the particles, giving also rise to the lowest possible suspension viscosity.
  • the present invention requires the use of a vehicle with a very low viscosity.
  • Such vehicles are known to those skilled in the art and comprise the class of liquids known as metabo usable oils.
  • oils include vegetable derived materials such as safflower oil, olive oil, soybean oil and sesame oil, and lipid esters such as those derived from caprylic and capric acid triglycerides.
  • metabo usable, biodegradable or biocompatible liquids which might be suitable belong to the class of saturated hydrocarbons, halogenated unsaturated ad saturated hydrocarbons and esters or ethers of these compounds.
  • Preferable vehicles are alkyl esters of oleic acid.
  • a particularly preferred example is ethyl oleate (EO), the ethyl ester of oleic acid, which is an anhydrous liquid with pharmaceutical regulatory approval for administration by the intramuscular and subcutaneous routes.
  • ethyl oleate As well as having very low viscosity (5.5mPas at 25°C), ethyl oleate has other properties that make it a suitable vehicle for the application in question including a very high boiling point ( ⁇ 205°C) and thus a very low vapour pressure prolonged oxidative stability, very low residual moisture content and rapid absorption by body tissues. In addition it exhibits a low chemical reactivity with the materials used in the delivery devices that are mentioned in this disclosure. Dispersion of any of the formulations 1-5 described in the Examples (produced by spray drying) in ethyl oleate resulted in the production of generally monodisperse particles suspension of with minimal clumping or aggregation of the particles. This was demonstrated by thorough analysis of the suspensions with optical analytical techniques like in-situ microscopy.
  • This specification details a method of lowering the relative density of particles in a controllable fashion such that the average relative density of the particle population is sufficiently similar to that of the metabo usable oil, for example ethyl oleate (0.87g/cm at 20 0 C) such that the particles neither float nor sink.
  • the method for lowering the density of the particles involves the incorporation of a gas generating compound into the aqueous formulation prior to spray drying.
  • ammonium bicarbonate is the preferred excipient as it is pharmaceutically generally regarded as safe and has the desired characteristics required to perform the density controlling process.
  • Other similar metal bicarbonate excipients are known and include sodium, calcium and potassium bicarbonate.
  • ammonium bicarbonate decomposes due to the heat of the process, liberating a mixture of carbon dioxide, water vapour and ammonium gasses in the approximate ratio of 56%, 23% and 21% respectively.
  • these gasses are produced at the exact same time that the particles are undergoing transition from a fluid liquid state to a viscous syrup state yet there is insufficient time for them to escape to the environment before the particles fully harden into the amorphous glass state.
  • the gasses are trapped within the rapidly drying particles forming enclosed gaseous voids within each particle.
  • the amount of ammonium bicarbonate present in the original aqueous formulation directly correlates with the size of the gaseous void present in the resulting glass particle and therefore ultimately controls the final density of the particle population.
  • the density of the particles with the low density of metabo usable oils, for example ethyl oleate and therefore prevent sedimentation of the particles during long term storage.
  • Long-term refers here to the period of time in which the drug reservoir is emptied which might range from a few weeks to 1 year.
  • Sedimentation refers here to the displacement of particles under the action of gravity in which the distance of displacement is substantially smaller than the smallest dimension of the drug reservoir, which typically is 1 cm or smaller.
  • the incorporation of this technology overcomes the issues of using high viscosity vehicles and gives full utility to the invention.
  • a stable dispersion is a strict requirement for accurately pumping suspensions out of a drug delivery device having a narrow orifice. Therefore, in accordance with the present invention the suspension preferably also comprises a dispersant. Effective dispersants adsorb on the surface of the particles while other parts of the dispersant molecule protrude away from the surface into the surrounding liquid, thereby providing the so-called steric barrier.
  • a wide variety of molecular structures is known that performs this task, for example homopolymers, block copolymers, graft copolymers, and surfactants.
  • the dispersant is selected in function of the nature of the surface of the particles and the properties of the surrounding liquid.
  • Suitable examples of dispersants for amorphous matrix particles in non-polar dispersion media often-used in medical formulations include substances such as such as lecithin, liposomes, phospholipids, pegylated hydrophobic polymers, pegylated liposomes (stealth liposomes), and alkylated polar polymers (e.g. poly alkyl cyanoacrylates). ,.
  • dispersants include substances such as polyethylene oxide-polypropylene oxide (PEO-PPO) block copolymers (examples of commercial products: Poloxamer, Pluronic), popyvinylpyrrolidone (PVP), polysorbate, and poly(lactic-co-glycolic acid) (PLGA).
  • PEO-PPO polyethylene oxide-polypropylene oxide
  • Pluronic Poloxamer, Pluronic
  • PVP popyvinylpyrrolidone
  • polysorbate poly(lactic-co-glycolic acid)
  • PLGA poly(lactic-co-glycolic acid)
  • the present invention also provides a drug delivery device for delivering to a patient in a controlled manner the suspension according to the present invention.
  • the present invention also relates to a drug delivery device which comprises a reservoir comprising the suspension according to the present invention and a means for releasing a discrete amount of the suspension from the drug delivery device.
  • the present drug delivery device further comprises a pump system being arranged for ejecting the discrete amount of the suspension.
  • the pump system used in accordance with the present invention is capable to provide delivery of the suspension at a flow rate of in the range of from 1-5000 micro liters per day.
  • the pump system used in accordance with the present invention is capable to provide delivery of the suspension at a flow rate of in the range of from 1-1000 micro liters per day.
  • the volume fraction of particles ⁇ in the suspension and the volume fraction of drugs in the particles ⁇ needs to be such that, given the reservoir volume of the implant V, the following condition is fulfilled:
  • W the amount (mass) of pharmaceutical ingredient that needs to be stored inside the device, which depends on the required daily dose and refill or explantation frequency if the device is non-refillable, and p the density of the pharmaceutical ingredient.
  • Suitable examples of the drug delivery systems in accordance with the present invention include implantable or insertable drug delivery devices, syringes, infusion sets, syringe pumps, modular ingestible drug delivery capsules (electronic pills), external infusion pumps, and transdermal reservoir systems.
  • the pumping system to be used in the present drug delivery device comprises a dose compartment for comprising at least the discrete amount of fluid, a piston for controlling a volume of the dose compartment and an actuator for controlling the piston.
  • the piston and the actuator are arranged such that activating the actuator causes the piston to decrease the volume of the dose compartment for releasing the discrete amount of fluid.
  • Another suitable pumping system is based on peristaltic fluid displacement. The applicability of the invention is however not limited to these pumping systems.
  • the present invention further relates to a method for preparing the suspension according to the present invention, which method comprises mixing the drug with the matrix excipient, resulting in a liquid formulation, spray drying the liquid formulation, resulting in particles, and - mixing the particles with the vehicle.
  • the present invention relates to the use of the suspension according to the invention for the treatment and/or prevention of a disease.
  • the present invention relates to the use of the drug delivery device according to the invention for the treatment and/or prevention of a disease.
  • diseases include hophilia, and other blood disorders, growth disorders, diabetes, leukemia, hepatitis, renal failure, HIV infection, herediraty diseases such as cerebrosidase deficiency and adenosine deaminase deficiency, hypertension, septic shock, autoimmune diseases such as multiple sclerosis, Graves disease, systemic lupus erythematosus and rheumatoid arthritis, shock and wasting disorders, cystic fibrosis, lactose intolerance, Crohn's disease, inher cancers. flammatory bowel disease, gastrointestinal and other cancers.
  • Fig. 1 shows an implanted pump delivering drugs intrathetically
  • Fig. 2 shows the determined level of active Betaseron (interferon-beta, an example of a therapeutic agent) in an aqueous solution over time for a number of temperatures
  • Fig. 3 shows the determined level of active Betaseron preserved in particles as well as particles in the vehicle ethyle oleate, according to the invention over time for a number of temperatures;
  • Fig. 4 shows an in-situ microscopic image of a suspension according to the invention
  • Fig. 5 shows an image from an electron microscope of particles according to the invention.
  • a Buchi B290 spray drier has been used.
  • the drier has a number of ranges for the aspiration rate: 20-50 per m 3 of drying gas, more preferably 25-45 per m 3 drying gas, the drying gas being preferably Nitrogen.
  • the outlet temperature of the drier has been varied in different experiments between 40 and 80 0 C.
  • the fluid pump rates ranged from 0.5 to 5 ml/min.
  • Interferon-beta IFN- ⁇ , Betaseron®
  • low concentration of interferon has been used in order to reduce the required amount of interferon for the experiments.
  • other experiments have shown that the advantages of the invention can easily be achieved with higher concentrations of the drug than the ones shown in the formulations below.
  • Rehydrated Betaseron® was mixed with aqueous solutions of trehalose, mannitol and calcium lactate such that the final excipient ratios expressed as w/w% were trehalose: 79.5 w/w%, mannitol: 4.2 w/w% and calcium lactate: 16.3 w/w%.
  • the interferon- beta concentration was 500 ⁇ g per gram powder.
  • the resulting liquid formulation was spray dried. 89.6% of the total solid content contained within the aqueous liquid formulation was collected from the spray drier as a fine powder
  • Rehydrated Betaseron® was mixed with aqueous solutions of trehalose and sucrose such that the final excipient ratios expressed as w/w % were trehalose: 80 w/w%, sucrose: 20 w/w%.
  • the interferon-beta concentration was 100 ⁇ g per gram powder.
  • the resulting liquid formulation was spray dried. 85.4% of the total solid content contained within the aqueous liquid formulation was collected from the spray drier as a fine powder.
  • Rehydrated Betaseron® was mixed with aqueous solutions of trehalose and sucrose containing 0.02M ammonium bicarbonate such that the final excipient ratios expressed as w/w % were trehalose: 80 w/w%, sucrose: 20 w/w%.
  • the interferon-beta concentration was 100 ⁇ g per gram powder.
  • the resulting liquid formulation was spray dried. 87.5% of the total solid content contained within the aqueous liquid formulation was collected from the spray drier as a fine powder
  • Formulation 4 Rehydrated Betaseron® was mixed with aqueous solutions of trehalose and mannitol such that the final excipient ratios expressed as w/w% were trehalose: 95 w/w%, mannitol: 5 w/w%.
  • the interferon-beta concentration was 100 ⁇ g per gram powder.
  • the resulting liquid formulation was spray dried. 81.6% of the total solid content contained within the aqueous liquid formulation was collected from the spray drier as a fine powder.
  • Rehydrated Betaseron® was mixed with aqueous solutions of trehalose and mannitol containing 0.02M ammonium bicarbonate such that the final excipient ratios expressed as w/w% were trehalose: 95 w/w%, mannitol: 5 w/w%.
  • the interferon-beta concentration was 189 ⁇ g per gram powder.
  • the resulting liquid formulation was spray dried. 82.4% of the total solid content contained within the aqueous liquid formulation was collected from the spray drier as a fine powder
  • Suspensions were prepared by suspending the spray dried powders into the vehicle under dry conditions, gently homogenizing powders in the vehcile by keeping them on roller bench for sufficient amount of time.
  • IFN- ⁇ The stability of IFN- ⁇ in the above formulations was determined using an enzyme-linked immunoassay (ELISA) that detects only bioactive IFN- ⁇ .
  • ELISA enzyme-linked immunoassay
  • the principle of ELISA is described in for example "Immunology", I. Roitt, J. Brostoff, D. Male, 5 th Ed., 1998, p. 386-395.
  • a known mass of micro-particulate powder containing a known mass of IFN- ⁇ was rehydrated with a known volume of aqueous diluent, for example water containing a defined concentration of an appropriate detergent, to create a solution with a known theoretical concentration of IFN- ⁇ .
  • aqueous diluent for example water containing a defined concentration of an appropriate detergent
  • aqueous extraction buffer typically water containing a defined concentration of an appropriate detergent.
  • the resultant oil/aqueous mixture is then gently mixed for a defined period of time at refrigerated temperatures (typically 2-8°C) in order for the oil and water phases to mix thoroughly.
  • refrigerated temperatures typically 2-8°C
  • the oil and aqueous phases separate with the oil floating on top of the more dense aqueous liquid.
  • the IFN- ⁇ is now to be found in the aqueous phase and can be used as if it were a powder sample simply rehydrated in an aqueous system.
  • Fig. 3 shows the determined level of Betaseron preserved in the particles without being suspended, as well as particle suspended in ethyl oleate according to the invention over time for a number of temperatures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une suspension pour utilisation thérapeutique dans un véhicule de particules comprenant un médicament, sur un procédé de préparation d'une telle suspension et sur l'utilisation d'une telle suspension pour le traitement et/ou la prévention d'une maladie. L'invention porte en outre sur un dispositif d'administration de médicament destiné à administrer une telle suspension et sur l'utilisation d'un tel dispositif d'administration de médicament pour le traitement et/ou la prévention d'une maladie.
PCT/IB2010/052676 2009-06-18 2010-06-15 Suspension de particules comprenant un médicament Ceased WO2010146536A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09163153.1 2009-06-18
EP09163153 2009-06-18

Publications (1)

Publication Number Publication Date
WO2010146536A1 true WO2010146536A1 (fr) 2010-12-23

Family

ID=42945986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/052676 Ceased WO2010146536A1 (fr) 2009-06-18 2010-06-15 Suspension de particules comprenant un médicament

Country Status (1)

Country Link
WO (1) WO2010146536A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
US20140369993A1 (en) * 2012-01-23 2014-12-18 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US9757459B2 (en) 2010-10-20 2017-09-12 Novaliq Gmbh Liquid pharmaceutical composition for the delivery of active ingredients
US9770508B2 (en) 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10064944B2 (en) 2010-11-11 2018-09-04 Novaliq Gmbh Liquid pharmaceutical composition for the treatment of a posterior eye disease
US10130707B2 (en) 2011-05-25 2018-11-20 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US10369117B2 (en) 2012-09-12 2019-08-06 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
US10507132B2 (en) 2016-06-23 2019-12-17 Novaliq Gmbh Topical administration method
US10682315B2 (en) 2015-09-30 2020-06-16 Novaliq Gmbh Semifluorinated compounds and their compositions
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
US11273174B2 (en) 2017-04-21 2022-03-15 Novaliq Gmbh Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032402A1 (fr) 2000-10-13 2002-04-25 Cambridge Biostability Ltd. Composition et procede pour liquides injectables stables
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
WO2005099669A1 (fr) 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquides contenant des particules de verre en suspension
WO2006083799A2 (fr) * 2005-02-03 2006-08-10 Alza Corporation Excipients en suspension, et suspensions pharmaceutiques pour des formes de dosages de medicaments
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon
WO2007026180A2 (fr) 2005-08-31 2007-03-08 Cambridge Biostability Limited Ameliorations apportees a la stabilisation de materiaux biologiques
EP1755650B1 (fr) 2004-05-25 2008-07-09 Intarcia Therapeutics, Inc. Une suspension contenant une biomolécule - d'une stabilité augmentée et d'une administration par un dispositif implantable

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
WO2002032402A1 (fr) 2000-10-13 2002-04-25 Cambridge Biostability Ltd. Composition et procede pour liquides injectables stables
WO2005099669A1 (fr) 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquides contenant des particules de verre en suspension
EP1755650B1 (fr) 2004-05-25 2008-07-09 Intarcia Therapeutics, Inc. Une suspension contenant une biomolécule - d'une stabilité augmentée et d'une administration par un dispositif implantable
WO2006083799A2 (fr) * 2005-02-03 2006-08-10 Alza Corporation Excipients en suspension, et suspensions pharmaceutiques pour des formes de dosages de medicaments
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon
WO2007026180A2 (fr) 2005-08-31 2007-03-08 Cambridge Biostability Limited Ameliorations apportees a la stabilisation de materiaux biologiques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABDUL-FATTAH, A. M ET AL., PHARM RES., vol. 24, 2007, pages 715
BOWEN P: "Particle Size Distribution Measurement from Millimeters to Nanometers and from Rods to Platelets", JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, TAYLOR AND FRANCIS GROUP, NEW YORK, NY, US LNKD- DOI:10.1081/DIS-120015368, vol. 23, no. 5, 1 January 2002 (2002-01-01), pages 631 - 662, XP009102859, ISSN: 0193-2691 *
ELBEIN, E. D ET AL., GLYCOBIOLOGY, vol. 13, 2003, pages 17
JIANG, G ET AL., J PHARM SCI., vol. 95, 2006, pages 80
MAA, Y. F. ET AL., J PHARM SCI., vol. 92, 2003, pages 319
ROSER, B., FUTURE MICROBIOL., vol. 1, 2006, pages 21

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US11324757B2 (en) 2010-03-17 2022-05-10 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10555953B2 (en) 2010-03-17 2020-02-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10525062B2 (en) 2010-03-17 2020-01-07 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US11160865B2 (en) 2010-10-20 2021-11-02 Novaliq Gmbh Liquid pharmaceutical composition for the delivery of active ingredients
US9757459B2 (en) 2010-10-20 2017-09-12 Novaliq Gmbh Liquid pharmaceutical composition for the delivery of active ingredients
US9968678B2 (en) 2010-10-20 2018-05-15 Novaliq Gmbh Liquid pharmaceutical composition for the delivery of active ingredients
US10064944B2 (en) 2010-11-11 2018-09-04 Novaliq Gmbh Liquid pharmaceutical composition for the treatment of a posterior eye disease
EP2676675A4 (fr) * 2011-02-18 2015-01-07 Stemdr Inc Composition contenant un inducteur de l'expression de sirt1 pour la prévention ou le traitement de la septicémie ou du choc septique
JP2014506889A (ja) * 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
EP3395356A1 (fr) * 2011-02-18 2018-10-31 Stemdr Inc. Composition contenant un inducteur de l'expression de sirt1 pour la prévention ou le traitement de la septicémie ou du choc septique
US11413333B2 (en) 2011-02-18 2022-08-16 Stemdr Inc. Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock
US10813999B2 (en) 2011-05-25 2020-10-27 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
US11844836B2 (en) 2011-05-25 2023-12-19 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
US10130707B2 (en) 2011-05-25 2018-11-20 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
US9757460B2 (en) * 2012-01-23 2017-09-12 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
USRE49758E1 (en) 2012-01-23 2023-12-19 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US20140369993A1 (en) * 2012-01-23 2014-12-18 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
US10058615B2 (en) 2012-09-12 2018-08-28 Novaliq Gmbh Semifluorinated alkane compositions
US10449164B2 (en) 2012-09-12 2019-10-22 Novaliq Gmbh Methods of treating ocular disorders using semifluorinated alkanes
US11583513B2 (en) 2012-09-12 2023-02-21 Novaliq Gmbh Semifluorinated alkane compositions
US10369117B2 (en) 2012-09-12 2019-08-06 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
US9770508B2 (en) 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
US12005033B2 (en) 2012-09-12 2024-06-11 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
US10576154B2 (en) 2012-09-12 2020-03-03 Novaliq Gmbh Semifluorinated alkane compositions
US11987623B2 (en) 2013-07-23 2024-05-21 Novaliq Gmbh Stabilized antibody compositions
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
US11357738B2 (en) 2015-09-30 2022-06-14 Novaliq Gmbh Semifluorinated compounds and their compositions
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
US12128010B2 (en) 2015-09-30 2024-10-29 Novaliq Gmbh Semifluorinated compounds and their compositions
US10682315B2 (en) 2015-09-30 2020-06-16 Novaliq Gmbh Semifluorinated compounds and their compositions
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
US10507132B2 (en) 2016-06-23 2019-12-17 Novaliq Gmbh Topical administration method
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US11400132B2 (en) 2016-09-23 2022-08-02 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
US11273174B2 (en) 2017-04-21 2022-03-15 Novaliq Gmbh Iodine compositions
US12150955B2 (en) 2017-04-21 2024-11-26 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
US12226422B2 (en) 2018-04-27 2025-02-18 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
US12059449B2 (en) 2018-10-12 2024-08-13 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11413323B2 (en) 2018-10-12 2022-08-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization

Similar Documents

Publication Publication Date Title
WO2010146536A1 (fr) Suspension de particules comprenant un médicament
KR101419583B1 (ko) 고농축 약물 입자, 제형, 현탁액 및 이들의 용도
US6939557B2 (en) Slow release protein polymers
EP1755650B1 (fr) Une suspension contenant une biomolécule - d'une stabilité augmentée et d'une administration par un dispositif implantable
US20090142399A1 (en) Dispersant agent for sustained-release preparations
CN1726008A (zh) 用于从植入装置中传递的稳定的非水单相凝胶及其制剂
EP1742616B1 (fr) Microsphères à libération continue et leurs méthodes de fabrication et d"utilisation
JP2006522133A (ja) 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
EP2266535B1 (fr) Formulation destinée à la libération contrôlée d'interferone par un copolymère bloc
WO2005039502A2 (fr) Compositions a base de macromeres fondus
WO2011007327A2 (fr) Suspension pour usage thérapeutique et dispositif d'administration de ladite suspension
Cunningham et al. Formulation of depot delivery systems
HK1235707A1 (en) Highly concentrated drug particles, formulations, suspensious and uses thereof
HK1235707A (en) Highly concentrated drug particles, formulations, suspensious and uses thereof
HK1238141A1 (en) Highly concentrated drug particles, formulations, suspensions and uses thereof
HK1152644B (en) Controlled release compositions for interferon based on block polymers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730229

Country of ref document: EP

Kind code of ref document: A1